+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

India Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Toxicology Testing), By Model Type, By End-use (Biopharmaceutical Companies, Government & Academic Institutes), And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 80 Pages
  • February 2024
  • Region: India
  • Grand View Research
  • ID: 5943903
Description Jump to:
The India preclinical CRO market is anticipated to reach USD 393.6 million by 2030 and is projected to grow at a CAGR of 11.4% from 2024 to 2030. The factors driving the growth are multifaceted, encompassing cost advantages, a skilled workforce, increasing outsourcing trends and R&D of clinical trials worldwide. According to a study on the CRO sector in India in August 2023 by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers Government of India, the aggregate R&D expenditure of the largest pharmaceutical corporations in 2022 exceeded USD 138 billion, up 1.7% from 2021.

The market growth is fueled by the rising trend of global outsourcing of research and development (R&D) functions. Industries such as pharmaceuticals, biotechnology, medical devices, and agrochemicals are leveraging the capabilities of CROs to carry out preclinical research studies. This allows pharmaceutical companies to delegate certain aspects of their R&D while focusing on their core competencies.

Advanced technologies such as high-throughput screening, silicon modeling, and advanced imaging have boosted preclinical CROs in India by speeding up drug discovery and development, making them faster and more accurate. Automation and robotics have also increased efficiency and reduced experiment turnaround times. India's large patient population, network of hospitals, and cost-effective operations with skilled human resources are expected to drive the market's growth.

India Preclinical CRO Market Report Highlights

  • Based on services, the toxicology testing segment led the market with a largest revenue share of 22.5% in 2023, owing to rising rate of outsourcing of non-core preclinical CRO research
  • Based on service, the bioanalysis and DMPK studies segment is expected to grow at the fastest CAGR over the forecast period, due to technological developmentsin analytical techniques, increased R&D in the pharmaceutical sector, and theshift to personalized medicine
  • Based on model types, the patient derived organoid (PDOs) models segment held the market with the largest revenue share of 80.6% in 2023, and is anticipated to witness the fastest CAGR during the forecast period, owing to theshift to personalized medicine, its use in drug development and disease modeling
  • Based on end-use, the biopharmaceutical companies segment held the market with largest revenue share of 85.0% in 2023, due to cost-effectiveness, access to advanced technologies, expertise, faster timelines, risk mitigation, and the ability to focus on core competencies
  • In May 2023, Aragen Life Sciences Ltd. and Far Biotech announced a partnership to advance preclinical initiatives in the field of neurodegeneration. Aragen will utilize its experimental discovery platform to help FAR Biotech reach an essential milestone in neurodegeneration with its small molecule program

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service
1.2.2. Model type
1.2.3. End use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Service outlook
2.2.2. Model type outlook
2.2.3. Application outlook
2.3. Competitive Insights
Chapter 3. India Preclinical CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. India Preclinical CRO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Legal landscape
3.3.2.6. Environmental landscape
Chapter 4. India Preclinical CRO Market: Service Estimates & Trend Analysis
4.1. Service Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. India Preclinical CRO Market by Service Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
4.4.1. Service
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.1. Bioanalysis and DMPK studies
4.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.1.1.1. In vitro ADME
4.4.1.1.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.1.1.2. In-vivo PK
4.4.1.1.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.2. Toxicology testing
4.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.2.1.1. GLP
4.4.1.1.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.2.1.2. Non-GLP
4.4.1.1.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3. Compound management
4.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3.1.1. Process R&D
4.4.1.1.3.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3.1.2. Custom synthesis
4.4.1.1.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.3.1.3. Others
4.4.1.1.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.4. Chemistry
4.4.1.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.4.1.1. Medicinal chemistry
4.4.1.1.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.4.1.2. Computation chemistry
4.4.1.1.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.5. Safety pharmacology
4.4.1.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1.6. Others
4.4.1.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Model type
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.1. Patient Derived Organoid (PDO) model
4.4.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.2. Patient derived xenograft model
4.4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. End use
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3.1.1. Biopharmaceutical companies
4.4.3.1.2. Government and academic institutes
4.4.3.1.3. Medical device companies
Chapter 5. India Preclinical CRO Market: Model Type Estimates & Trend Analysis
5.1. Model Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. India Preclinical CRO Market by Model Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
5.4.1. Patient Derived Organoid (PDO) model
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Patient derived xenograft model
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. India Preclinical CRO Market: End Use Estimates & Trend Analysis
6.1. End use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. India Preclinical CRO Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
6.4.1. Biopharmaceutical companies
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Government and academic institutes
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Medical device companies
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company heat map analysis, 2023
7.4. Company Profiles
7.4.1. Syngene International Limited
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Dabur Research
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. JSS Medical Research
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Jubilant Biosys Ltd.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Sugen Life Sciences
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Eurofins Advinus
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. GVRP
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Veeda Clinical Research Limited
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Axis Clinicals
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Syneos Health
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Ethicare-cro
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Liveon Biolabs Pvt.Ltd.
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. IQVIA Inc
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. Bioneeds
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. TheraIndx Lifesciences Pvt. Ltd.
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 India preclinical CRO market, by service, 2018 - 2030 (USD Million)
Table 3 India preclinical CRO market, by model type, 2018 - 2030 (USD Million)
Table 4 India preclinical CRO market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Market research approaches
Fig. 4 Value-chain-based sizing & forecasting
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 India preclinical CRO market: market outlook
Fig. 8 India preclinical CRO competitive insights
Fig. 9 Parent market outlook
Fig. 10 Related/ancillary market outlook
Fig. 11 Penetration and growth prospect mapping
Fig. 12 Industry value chain analysis
Fig. 13 India preclinical CRO market driver impact
Fig. 14 India preclinical CRO market restraint impact
Fig. 15 India preclinical CRO market strategic initiatives analysis
Fig. 16 India preclinical CRO market: Service movement analysis
Fig. 17 India preclinical CRO market: Service outlook and key takeaways
Fig. 18 Bioanalysis and DMPK studies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 In vitro ADME market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 In-vivo PK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Toxicology testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 GLP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Non-GLP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Compound management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Process R&D market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Custom synthesis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Medicinal chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Computation chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Safety pharmacology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 India preclinical CRO market: Model type movement analysis
Fig. 34 India preclinical CRO market: Model type outlook and key takeaways
Fig. 35 Patient Derived Organoid (PDO) model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Patient derived xenograft model market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 India preclinical CRO market: End use movement analysis
Fig. 38 India preclinical CRO market: End use outlook and key takeaways
Fig. 39 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Government and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • Syngene International Limited
  • Dabur Research
  • JSS Medical Research
  • Jubilant Biosys Ltd.
  • Sugen Life Sciences
  • Eurofins Advinus
  • GVRP
  • Veeda Clinical Research Limited
  • Axis Clinicals
  • Syneos Health
  • Ethicare-cro
  • Liveon Biolabs Pvt.Ltd.
  • IQVIA Inc
  • Bioneeds
  • TheraIndx Lifesciences Pvt. Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages80
PublishedFebruary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 183.3 Million
Forecasted Market Value ( USD ) by 2030 $ 393.6 Million
Compound Annual Growth Rate11.4%
Regions CoveredIndia
No. of Companies Mentioned15

Related Topics

Related Reports

In Vivo CRO Market Size, Share & Trends Analysis Report by Model Type (Rodent Based, Non-rodent Based), Modality (Small Molecule, Large Molecule), Indication, GLP Type (Non GLP, GLP Toxicology), Region, and Segment Forecasts, 2024-2030 - Product Image

In Vivo CRO Market Size, Share & Trends Analysis Report by Model Type (Rodent Based, Non-rodent Based), Modality (Small Molecule, Large Molecule), Indication, GLP Type (Non GLP, GLP Toxicology), Region, and Segment Forecasts, 2024-2030

  • Report
  • 257 Pages
  • Global
From
Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Preclinical CRO Market by Services, Application, End-User - Global Forecast 2025-2030 - Product Image

Preclinical CRO Market by Services, Application, End-User - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Preclinical CRO Global Market Report 2024 - Product Image

Preclinical CRO Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions - Product Image

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions

  • Report
  • 343 Pages
  • Global
From

About the Preclinical CRO Market

The Preclinical CRO market is a subset of the Drug Discovery industry, focusing on the preclinical stages of drug development. Preclinical CROs provide services such as drug safety testing, pharmacology studies, and toxicology studies. These services are used to assess the safety and efficacy of potential drugs before they are tested in humans. Preclinical CROs also provide services such as drug metabolism and pharmacokinetics, which are used to understand how a drug is absorbed, distributed, metabolized, and eliminated in the body. Preclinical CROs are an important part of the drug discovery process, as they provide the data needed to move a drug candidate forward in the development process. Preclinical CROs are also used to reduce the cost and time associated with drug development, as they can provide the data needed to make decisions quickly and efficiently. Some companies in the Preclinical CRO market include Charles River Laboratories, WuXi AppTec, Covance, PRA Health Sciences, and Envigo. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.